Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of vorinostat (RVL-001) in patients with Pitt Hopkins Syndrome (PTHS)

Next Previous
Search
Trial Profile

Study of vorinostat (RVL-001) in patients with Pitt Hopkins Syndrome (PTHS)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 07 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Pitt-Hopkins syndrome
  • Focus Adverse reactions; Proof of concept

Most Recent Events

  • 29 Apr 2025 According to an Unravel Biosciences media release, Company announced the submission of clinical study applications for RVL-001 under a pilot program by the Colombian Health Regulatory Agency ("INVIMA"), allowing for priority review and fast track approval for orphan and high unmet need diseases.
  • 24 Oct 2024 According to an Unravel Biosciences media release, initiation of patient dosing for the RVL-001 trial in RTT and extension trial in PTHS are both anticipated in early 2025.
  • 14 Jun 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top